TriPRIL CAR T
TriPRIL CAR T Cells in Multiple Myeloma
What's the purpose of the trial?
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells.
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C42.363201%2C-71.068802&zoom=10)
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
- TriPRIL CAR T Cells are a new CAR T-cell based therapy currently in development. Also called TriPRIL CAR T-cells, researchers believe this drug may allow them to target myeloma cells that are both BCMA positive and negative, as well as myeloma cells that express transmembrane activator and calcium-modulator and cyclophilin ligand (TACI).
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.